These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37708619)

  • 21. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
    Emsellem HA; Thorpy MJ; Lammers GJ; Shapiro CM; Mayer G; Plazzi G; Chen D; Carter LP; Villa KF; Lee L; Menno D; Black J; Dauvilliers Y
    Sleep Med; 2020 Mar; 67():128-136. PubMed ID: 31926465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
    Thorpy MJ; Shapiro C; Mayer G; Corser BC; Emsellem H; Plazzi G; Chen D; Carter LP; Wang H; Lu Y; Black J; Dauvilliers Y
    Ann Neurol; 2019 Mar; 85(3):359-370. PubMed ID: 30694576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced interference by phenothiazines in amphetamine drug of abuse immunoassays.
    Melanson SE; Lee-Lewandrowski E; Griggs DA; Long WH; Flood JG
    Arch Pathol Lab Med; 2006 Dec; 130(12):1834-8. PubMed ID: 17149959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
    Dauvilliers Y; Shapiro C; Mayer G; Lammers GJ; Emsellem H; Plazzi G; Chen D; Carter LP; Lee L; Black J; Thorpy MJ
    CNS Drugs; 2020 Jul; 34(7):773-784. PubMed ID: 32588401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions.
    Devine JK; Schwartz L; Hursh S; Asin J; de Vries N; Vonk PE; Vermeeren A; Donjacour CEHM; Vinckenbosch F; Ramaekers JG; Janssen H; Wang G; Chen D; Carter LP; Overeem S; Lammers GJ
    Neurol Ther; 2023 Feb; 12(1):249-265. PubMed ID: 36494591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay.
    Casey ER; Scott MG; Tang S; Mullins ME
    J Med Toxicol; 2011 Jun; 7(2):105-8. PubMed ID: 21191682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ranitidine interference with standard amphetamine immunoassay.
    Liu L; Wheeler SE; Rymer JA; Lower D; Zona J; Peck Palmer OM; Tamama K
    Clin Chim Acta; 2015 Jan; 438():307-8. PubMed ID: 25242739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methamphetamine and amphetamine isomer concentrations in human urine following controlled Vicks VapoInhaler administration.
    Smith ML; Nichols DC; Underwood P; Fuller Z; Moser MA; Flegel R; Gorelick DA; Newmeyer MN; Concheiro M; Huestis MA
    J Anal Toxicol; 2014 Oct; 38(8):524-7. PubMed ID: 25217541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The trazodone metabolite meta-chlorophenylpiperazine can cause false-positive urine amphetamine immunoassay results.
    Baron JM; Griggs DA; Nixon AL; Long WH; Flood JG
    J Anal Toxicol; 2011 Jul; 35(6):364-8. PubMed ID: 21740694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Performance of immunoassays in screening for opiates, cannabinoids and amphetamines in post-mortem blood.
    Hino Y; Ojanperä I; Rasanen I; Vuori E
    Forensic Sci Int; 2003 Jan; 131(2-3):148-55. PubMed ID: 12590054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
    Videnovic A; Amara AW; Comella C; Schweitzer PK; Emsellem H; Liu K; Sterkel AL; Gottwald MD; Steinerman JR; Jochelson P; Zomorodi K; Hauser RA
    Mov Disord; 2021 Oct; 36(10):2408-2412. PubMed ID: 34191352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study.
    Strollo PJ; Hedner J; Collop N; Lorch DG; Chen D; Carter LP; Lu Y; Lee L; Black J; Pépin JL; Redline S;
    Chest; 2019 Feb; 155(2):364-374. PubMed ID: 30471270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. False-Positive Amphetamines in Urine Drug Screens: A 6-Year Review.
    Pope JD; Drummer OH; Schneider HG
    J Anal Toxicol; 2023 Mar; 47(3):263-270. PubMed ID: 36367744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy.
    Malhotra A; Strollo PJ; Pepin JL; Schweitzer P; Lammers GJ; Hedner J; Redline S; Chen D; Chandler P; Bujanover S; Strohl K
    Sleep Med; 2022 Dec; 100():165-173. PubMed ID: 36084494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dimethylamylamine: a drug causing positive immunoassay results for amphetamines.
    Vorce SP; Holler JM; Cawrse BM; Magluilo J
    J Anal Toxicol; 2011 Apr; 35(3):183-7. PubMed ID: 21439156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amphetamine positive urine toxicology screen secondary to atomoxetine.
    Fenderson JL; Stratton AN; Domingo JS; Matthews GO; Tan CD
    Case Rep Psychiatry; 2013; 2013():381261. PubMed ID: 23424703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food.
    Zomorodi K; Kankam M; Lu Y
    Clin Ther; 2019 Feb; 41(2):196-204. PubMed ID: 30598342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and evaluation of an improved method for screening of amphetamines.
    Shindelman J; Mahal J; Hemphill G; Pizzo P; Coty WA
    J Anal Toxicol; 1999 Oct; 23(6):506-10. PubMed ID: 10517558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The analytical performance of six urine drug screens on cobas 6000 and ARCHITECT i2000 compared to LC-MS/MS gold standard.
    Abou El Hassan M; Colantonio D; Likhodii S; Nassar BA
    Clin Biochem; 2021 Jul; 93():99-103. PubMed ID: 33844982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kavain Interference with Amphetamine Immunoassay.
    Madhavaram H; Patel T; Kyle C
    J Anal Toxicol; 2020 Dec; ():. PubMed ID: 33326560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.